

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

APC anti-human CD3

RRID:AB_314066

Type: Antibody

Proper Citation

BioLegend Cat# 300412, RRID:AB_314066

Antibody Information

URL: http://antibodyregistry.org/AB_314066

Proper Citation: BioLegend Cat# 300412, RRID:AB_314066

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_314066

Vendor: BioLegend

Catalog Number: 300412

Alternative Catalog Numbers: 300411, 300439, 300458

Record Creation Time: 20250819T215741+0000

Record Last Update: 20250820T003923+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD3.

No alerts have been found for APC anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wang R, et al. (2025) An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B β 1/2 shedding. *Cell reports. Medicine*, 6(3), 101981.

Tang M, et al. (2025) Single cell immune profiling in ankylosing spondylitis reveals resistance of CD8+ T cells to immune exhaustion. *iScience*, 28(7), 112715.

Lam N, et al. (2025) Asynchronous aging and turnover of human circulating and tissue-resident memory T cells across sites. *Immunity*, 58(9), 2271.

Burnell SEA, et al. (2025) OSCAR is an online ML-powered tool for organoid cell counting using bright-field images. *Cell reports methods*, 5(12), 101251.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. *Clinical and experimental immunology*.

Lanman NA, et al. (2024) Infiltrating lipid-rich macrophage subpopulations identified as a regulator of increasing prostate size in human benign prostatic hyperplasia. *Frontiers in immunology*, 15, 1494476.

Schmit MM, et al. (2024) A critical threshold of MCM10 is required to maintain genome stability during differentiation of induced pluripotent stem cells into natural killer cells. *Open biology*, 14(1), 230407.

Steitz AM, et al. (2023) TRAIL-dependent apoptosis of peritoneal mesothelial cells by NK cells promotes ovarian cancer invasion. *iScience*, 26(12), 108401.

Chen Y, et al. (2023) Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity. *Cell reports*, 42(8), 112827.

Ling X, et al. (2022) Efficient generation of locus-specific human CAR-T cells with CRISPR/cCas12a. *STAR protocols*, 3(2), 101321.

Ding S, et al. (2022) Patient-derived micro-organospheres enable clinical precision oncology. *Cell stem cell*, 29(6), 905.

Ye L, et al. (2022) A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. *Cell metabolism*, 34(4), 595.

Wang Y, et al. (2021) NAD⁺ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. *Cell reports*, 36(6), 109516.

Ling X, et al. (2021) Improving the efficiency of CRISPR-Cas12a-based genome editing with site-specific covalent Cas12a-crRNA conjugates. *Molecular cell*, 81(22), 4747.

Zhang B, et al. (2021) Photoswitchable CAR-T Cell Function In Vitro and In Vivo via a Cleavable Mediator. *Cell chemical biology*, 28(1), 60.

Wang C, et al. (2021) CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. *Cell stem cell*, 28(9), 1597.

Constantinescu-Bercu A, et al. (2020) Activated α IIb β 3 on platelets mediates flow-dependent NETosis via SLC44A2. *eLife*, 9.

Li W, et al. (2020) Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. *Immunity*, 53(2), 456.

Sade-Feldman M, et al. (2018) Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. *Cell*, 175(4), 998.